101 results match your criteria: "MD (G.A.M.); and the School of Medicine and Telehealth Center[Affiliation]"
Aliment Pharmacol Ther
January 2025
Department of Gastroenterology and Hepatology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Mult Scler
October 2024
Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine, Fondazione PTV Policlinico Tor Vergata, Tor Vergata University, Rome, Italy.
Ther Adv Med Oncol
August 2024
Department of Epidemiology and Data Science, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Background: Current patient selection for adjuvant chemotherapy (ACT) after curative surgery for stage II colon cancer (CC) is suboptimal, causing overtreatment of high-risk patients and undertreatment of low-risk patients. Postoperative circulating tumor DNA (ctDNA) could improve patient selection for ACT.
Objectives: We conducted an early model-based evaluation of the (cost-)effectiveness of ctDNA-guided selection for ACT in stage II CC in the Netherlands to assess the conditions for cost-effective implementation.
Clin Lung Cancer
November 2024
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address:
Circulation
October 2024
Advanced Aortic Research Program, Division of Vascular and Endovascular Surgery, Department of Cardiothoracic & Vascular Surgery, McGovern Medical School, University of Texas Health Science Center at Houston (E.R.T., G.S.O., M.D.N.).
Background: Physician modified endografts (PMEGs) have been widely used in the treatment of complex abdominal aortic aneurysm and thoracoabdominal aortic aneurysm, however, previous data are limited to small single center studies and robust data on safety and effectiveness of PMEGs are lacking. We aimed to perform an international multicenter study analyzing the outcomes of PMEGs in complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms.
Methods: An international multicenter single-arm cohort study was performed analyzing the outcomes of PMEGs in the treatment of elective, symptomatic, and ruptured complex abdominal aortic aneurysms and thoracoabdominal aortic aneurysms.
J Thromb Haemost
September 2024
Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam Univesity Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Cardiovascular Sciences, Pulmonary Hypertension and Thrombosis, Amsterdam, the Netherlands; Department of Internal Medicine, Tergooi MC, Hilversum, the Netherlands.
Background: Guidelines suggest indefinite anticoagulation after unprovoked venous thromboembolism (VTE) unless the bleeding risk is high, yet there is no consistent guidance on assessing bleeding risk.
Objectives: This study aimed to evaluate the performance of 5 bleeding risk tools (RIETE, VTE-BLEED, CHAP, VTE-PREDICT, and ABC-Bleeding).
Methods: PLATO-VTE, a prospective cohort study, included patients aged ≥40 years with a first unprovoked VTE.
N Engl J Med
August 2024
From Clinica São Germano (V.H.) and Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo (G.A.M.), São Paulo, Centro de Pesquisa e Ensino em Saúde de Santa Catarin, Florianópolis (A.C.R.A.), and Universidade da Região de Joinville and Centro de Hematologia e Oncologia, Joinville (M.P.L.) - all in Brazil; Medical University of Lodz, Lodz (P.R.), Medical University of Lublin, Lublin (M.H., M.M.), and the Medical University of Silesia, Katowice (S.G.) - all in Poland; Gorodskaya Klinicheskaya Bol'nitsa Imeni Saint Petersburg Botkina, Moscow (V.Z.); the Royal North Shore Hospital (C.W.) and Liverpool Hospital (A.B.), Sydney, Royal Prince Alfred Hospital and University of Sydney, Camperdown, NSW (P.J.H.), and Pindara Private Hospital, Gold Coast, QLD (H.S.) - all in Australia; the Department of Hematooncology, University Hospital Ostrava, and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic (R.H.); Sungkyunkwan University and Samsung Medical Center, Seoul, South Korea (K.K.); Institut Català d'Oncologia-L'Hospitalet de Llobregat-Barcelona, Barcelona (A.M.S.B.), Institut Català d'Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona (A.O.), and Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Ciberonc, Salamanca (M.-V.M.) - all in Spain; Cross Cancer Institute, Edmonton (I.S.), and GSK, Mississauga (H.B.) - both in Canada; the Hematology Unit, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori," IRST IRCCS, Meldola (C.C.), and IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Bologna (M.C.) - both in Italy; Christchurch Hospital, Christchurch, New Zealand (P.G.); National and Kapodistrian University of Athens, Athens (M.D.); the First Affiliated Hospital of Soochow University, Suzhou, China (C.F.); University Hospitals of Leicester NHS Trust, Leicester (M.G.), GSK, Stevenage (A.M., S.M.), and GSK, London (L.E.) - all in the United Kingdom; University of Kansas Cancer Center, Fairway (A.-O.A.); the Department of Hematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel (M.E.G.); Rocky Mountain Cancer Centers-Denver-Midtown, Denver (R. Rifkin); Matsuyama Red Cross Hospital, Matsuyama, Japan (T.F.); GSK, Upper Providence, PA (N.P., X.Z., R. Rogers, S.R.-G., J.O.); and GSK, Durham (M.N.), and GSK, Research Triangle Park (E.L.) - both in North Carolina.
Background: Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care therapies.
Methods: In this phase 3, open-label, randomized trial, we evaluated belantamab mafodotin, bortezomib, and dexamethasone (BVd), as compared with daratumumab, bortezomib, and dexamethasone (DVd), in patients who had progression of multiple myeloma after at least one line of therapy. The primary end point was progression-free survival.
Mol Ther
August 2024
AstraZeneca, Early Vaccines & Immune Therapies, Gaithersburg, MD 20878, USA.
Single monoclonal antibodies (mAbs) can be expressed in vivo through gene delivery of their mRNA formulated with lipid nanoparticles (LNPs). However, delivery of a mAb combination could be challenging due to the risk of heavy and light variable chain mispairing. We evaluated the pharmacokinetics of a three mAb combination against Staphylococcus aureus first in single chain variable fragment scFv-Fc and then in immunoglobulin G 1 (IgG1) format in mice.
View Article and Find Full Text PDFNeurooncol Adv
March 2024
Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Background: POLARIS (phase 2 [ph2]; NCT03911869) evaluated encorafenib (BRAF inhibitor) in combination with binimetinib (MEK1/2 inhibitor) in BRAF/MEK inhibitor-naïve patients with V600-mutant melanoma with asymptomatic brain metastases.
Methods: The safety lead-in (SLI) assessed tolerability for high-dose encorafenib 300 mg twice daily (BID) plus binimetinib 45 mg BID. If the high dose was tolerable in ph2, patients would be randomized to receive high or standard dose (encorafenib 450 mg once daily [QD] plus binimetinib 45 mg BID).
J Allergy Clin Immunol
August 2024
InBio, Charlottesville, Va.
Background: Human IgE (hIgE) mAbs against major mite allergen Der p 2 developed using human hybridoma technology were used for IgE epitope mapping and analysis of epitopes associated with the hIgE repertoire.
Objective: We sought to elucidate the new hIgE mAb 4C8 epitope on Der p 2 and compare it to the hIgE mAb 2F10 epitope in the context of the allergenic structure of Der p 2.
Methods: X-ray crystallography was used to determine the epitope of anti-Der p 2 hIgE mAb 4C8.
Heart failure (HF) is a well-described final common pathway for a broad range of diseases however substantial confusion exists regarding how to describe, study, and track these underlying etiologic conditions. We describe (1) the overlap in HF etiologies, comorbidities, and case definitions as currently used in HF registries led or managed by members of the global HF roundtable; (2) strategies to improve the quality of evidence on etiologies and modifiable risk factors of HF in registries; and (3) opportunities to use clinical HF registries as a platform for public health surveillance, implementation research, and randomized registry trials to reduce the global burden of noncommunicable diseases. Investment and collaboration among countries to improve the quality of evidence in global HF registries could contribute to achieving global health targets to reduce noncommunicable diseases and overall improvements in population health.
View Article and Find Full Text PDFNutrients
January 2024
Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA.
(1) Vitamin D deficiency is associated with mortality in the general population and has been observed in one rheumatoid arthritis (RA) cohort. Here, we investigate the relationship between 25-hydroxyvitamin D (25(OH)D) levels before methotrexate (MTX) therapy initiation in patients with RA and the subsequent all-cause mortality in a national Veterans Affairs (VA) cohort. (2) This is a retrospective study on RA patients time-oriented around the initial MTX prescription and 25(OH)D levels before starting MTX.
View Article and Find Full Text PDFPost-acute sequelae of SARS-CoV-2 (PASC) is a significant public health concern. We describe Patient Reported Outcomes (PROs) on 590 participants prospectively assessed from hospital admission for COVID-19 through one year after discharge. Modeling identified 4 PRO clusters based on reported deficits (minimal, physical, mental/cognitive, and multidomain), supporting heterogenous clinical presentations in PASC, with sub-phenotypes associated with female sex and distinctive comorbidities.
View Article and Find Full Text PDFCell Rep
January 2024
Broad Institute of MIT and Harvard University, Cambridge, MA, USA; Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA; Massachusetts Consortium on Pathogen Readiness, Boston, MA, USA; Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
Targeted synthetic vaccines have the potential to transform our response to viral outbreaks, yet the design of these vaccines requires a comprehensive knowledge of viral immunogens. Here, we report severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) peptides that are naturally processed and loaded onto human leukocyte antigen-II (HLA-II) complexes in infected cells. We identify over 500 unique viral peptides from canonical proteins as well as from overlapping internal open reading frames.
View Article and Find Full Text PDFACS Chem Biol
August 2023
Department of Pharmacology, Vanderbilt University, Nashville, Tennessee 37232, United States.
-Acyl-phosphatidylethanolamine hydrolyzing phospholipase D (NAPE-PLD) is a zinc metallohydrolase that hydrolyzes -acyl-phosphatidylethanolamines (NAPEs) to form -acyl-ethanolamines (NAEs) and phosphatidic acid. Several lines of evidence suggest that reduced NAPE-PLD activity could contribute to cardiometabolic diseases. For instance, expression is reduced in human coronary arteries with unstable atherosclerotic lesions, defective efferocytosis is implicated in the enlargement of necrotic cores of these lesions, and NAPE-PLD products such as palmitoylethanolamide and oleoylethanolamide have been shown to enhance efferocytosis.
View Article and Find Full Text PDFNature
August 2023
Wilf Family Department of Politics, New York University, New York, NY, USA.
Many critics raise concerns about the prevalence of 'echo chambers' on social media and their potential role in increasing political polarization. However, the lack of available data and the challenges of conducting large-scale field experiments have made it difficult to assess the scope of the problem. Here we present data from 2020 for the entire population of active adult Facebook users in the USA showing that content from 'like-minded' sources constitutes the majority of what people see on the platform, although political information and news represent only a small fraction of these exposures.
View Article and Find Full Text PDFNeurology
September 2023
From the Gordon Center for Medical Imaging (P.C.P., N.E.-D., J.S., E.A.K., M.D.N., G.E.F., K.A.J., H.I.L.J.), Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston; Faculty of Health (N.E.-D., H.I.L.J.), Medicine and Life Sciences, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht University, The Netherlands; Department of Neurology (A.P.S., K.V.P., G.A.M., D.R., R.A.S., K.A.J.), Massachusetts General Hospital, Harvard Medical School; The Athinoula A. Martinos Center for Biomedical Imaging (A.P.S.), Department of Radiology, Massachusetts General Hospital, Harvard Medical School; and Center for Alzheimer Research and Treatment (K.V.P., G.A.M., D.R., R.A.S., K.A.J.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
Background And Objectives: The predictable Braak staging scheme suggests that cortical tau progression may be related to synaptically connected neurons. Animal and human neuroimaging studies demonstrated that changes in neuronal activity contribute to tau spreading. Whether similar mechanisms explain tau progression from the locus coeruleus (LC), a tiny noradrenergic brainstem nucleus involved in novelty, learning, and memory and among the earliest regions to accumulate tau, has not yet been established.
View Article and Find Full Text PDFCommun Med (Lond)
May 2023
Sanofi, Vaccines R&D, Marcy l'Etoile, France.
Background: Since the beginning of the COVID-19 pandemic, several variants of concern (VOC) have emerged for which there is evidence of an increase in transmissibility, more severe disease, and/or reduced vaccine effectiveness. Effective COVID-19 vaccine strategies are required to achieve broad protective immunity against current and future VOC.
Methods: We conducted immunogenicity and challenge studies in macaques and hamsters using a bivalent recombinant vaccine formulation containing the SARS-CoV-2 prefusion-stabilized Spike trimers of the ancestral D614 and the variant Beta strains with AS03 adjuvant (CoV2 preS dTM-AS03) in a primary immunization setting.
Neurology
June 2023
From the Department of Neurology (H.A.-H., H.A., T.H.), Aarhus University Hospital, Denmark; Department of Neurology (A.Y.D., B.v.d.B., C.V., J.R., S.E.L., S. Arends, L.W.G.L., K.K., B.C.J.), Erasmus MC, University Medical Centre Rotterdam, the Netherlands; Department of Neurology (A.M.S.), University of Michigan School of Medicine, Ann Arbor; Department of Neurology (S.A.Z.), University of Pittsburgh Medical Center, PA; Department of Neurology (H.J.W., A.D.), College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom; Department of Neurology (D.R.C.), Johns Hopkins University School of Medicine, Baltimore, MD; Department of Neurology (K.C.G.), St. Elizabeth's Medical Centre, Tufts University, School of Medicine, Boston, MA; Laboratory of Gut-Brain Signaling (Z.I.); Laboratory Sciences and Services Division (LSSD) (Z.I.), icddr,b; National Institute of Neurosciences and Hospital (Q.D.M.), Dhaka, Bangladesh; Department of Neurology (S.H.S.), Odense University Hospital and University of Southern Denmark; Department of Neurology (S. Kusunoki), Kindai University Faculty of Medicine, Osaka-Sayama City, Japan; Department of Neurology (C.C.), Neuromuscular Unit, Bellvitge University Hospital-IDIBELL, CIBERER, Barcelona, Spain; Division of Neurology (K.B.), Department of Medicine, Groote Schuur Hospital, University of Cape Town, South Africa; Department of Neurology (J.A.L.M.), Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, United Kingdom; Department of Neurology (B.v.d.B., H.K.), Franciscus Gasthuis & Vlietland (location: Vlietland Hospital), Schiedam; Department of Neurology (S. Arends, P.W.W.), Haga Hospital, Den Haag; Department of Neurology (L.W.G.L., L.H.V.), St. Elisabeth-TweeSteden Hospital, Tilburg, the Netherlands; Department of Neurology (L.B.), IRCCS Ospedale Policlinico San Martino, Genova, Italy; Department of Neurology (S. Kuwabara), Chiba University, Chuo-ku, Japan; Department of Neurology (P.V.d.B.), Neuromuscular Reference Centre, University Hospital Saint-Luc, University of Louvain, Brussels, Belgium; Department of Neurology (S.M.), Hospital de Pediatría J.P. Garrahan, Buenos Aires, Argentina; Dysimmune Neuropathies Unit (G.A.M.), Department of Systems Medicine, Tor Vergata University Hospital, Rome, Italy; Department of Medicine (N.S.), University of Malaya, Kuala Lumpur, Malaysia; Department of Neurology (G.G.), University Hospital of Modena, Italy; Department of Clinical Neurophysiology (Y.P.), Reference Centre for NMD, CHU Nantes, Nantes, France; Department of Neurology (J.B.), Saarland University Medical School, Homburg (previous hospital), and MVZ Pfalzklinikum (J.B.), Kusel, Germany (current hospital); Department of Neurology (K.K., R.P.K.), Albert Schweitzer Hospital, Dordrecht, the Netherlands; Department of Neurology (C.M.), Hospital Británico, Buenos Aires, Argentina; Department of Neurology (M.J.S.T.), Hospital Marques de Valdecilla, Santander; Department of Neurology (L.Q., L.M.-A.), Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, CIBERER and ERN-NMD, Spain; Department of Neurology (Y.W.), Affiliated Hospital of Jining Medical University, Shandong Province, China; Neuromuscular and Neuroimmunology Service (E.N.-O.), IRCCS Humanitas Research Hospital, Milan University, Italy; Nuffield Department of Clinical Neurosciences (S.R.), University of Oxford and Oxford University Hospitals NHS Foundation Trust, United Kingdom; Department of Neurosciences, Ophthalmology, Rehabilitation, Genetics and Maternal Sciences (A.S.), University of Genova, and IRCCS San Martino Hospital (A.S.), Genova, Italy; Department of Neurology (J.P.), Hospital Clínico de Santiago, Travesia Choupana, Santiago de Compostela (A Coruña), Spain; Department of Neurology (F.H.V.), Franciscus Gasthuis & Vlietland (location: Franciscus Gasthuis), Rotterdam, the Netherlands; Department of Neurology (W.W., N.K.), University of Vermont Medical Centre, Burlington; Department of Neurology (H.C.L.), University Hospital of Cologne, Germany; Department of Neurology (V.G., B.S.), Montefiore Medical Center, Bronx, NY; Department of Neurology (G.C.), University Milano-Bicocca, Monza, Italy; Department of Neurology (G.G.-G.), Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Spain; Department of Neurology (F.A.B.), Instituto de Investigaciones Neurológicas Raúl Carrea, FLENI, Buenos Aires, Argentina; Department of Neurology (H.D.K.), University Health Network, University of Toronto, Ontario, Canada; Department of Neurology (E.D.), University Hospital of Larissa, Greece; Department of Neurology (S. Attarian), Reference Centre for NMD, CHU Timone ERN NMD, Marseille, France; Department of Neurology (A.J.v.d.K., F.E.), Amsterdam University Medical Centre, University of Amsterdam, Neuroscience Institute; Department of Neurology (J.P.A.S.), Maasstad Hospital, Rotterdam; Department of Neurology (H.J.G.), Reinier de Graaf Hospital, Reinier de Graafweg, Delft, the Netherlands; Department of Neurology (R.D.M.H.), King's College Hospital, Denmark Hill, London; Department of Neurology (J.K.L.H.), The Walton Centre, Liverpool, United Kingdom; Department of Neurology (K.A.S.), University of Texas Health Science Centre at Houston; Department of Biology (N.K., S. Karafiath), Utah Valley University, Orem; Department of Neurology (M.V.), Lahey Hospital and Medical Center, Tufts University School of Medicine, Burlington, MA; Department of Neurology, Mental Health and Sensory Organs (NESMOS) (G.A.), Faculty of Medicine and Psychology, University of Rome "Sapienza," Sant' Andrea Hospital, Italy; Department of Clinical Neurosciences (T.E.F.), University of Calgary, Alberta, Canada; Department of Neurology (C.F.), Maastricht University Medical Centre, the Netherlands; Department of Neurology (M.B.), Leeds Teaching Hospitals; Department of Neurology (R.C.R.), Addenbrooke's Hospital, Cambridge, United Kingdom; Department of Neurology (N.J.S.), University at Buffalo Jacobs School of Medicine and Biomedical Sciences, NY; Department of Neurology (R.F.), Scientific Institute San Raffaele, Milano, Italy; Department of Neurology (G.W.v.D.), Canisius Wilhelmina Hospital, Nijmegen; Department of Neurology (M.P.J.G.), Jeroen Bosch Hospital, 's-Hertogenbosch; Department of Neurology (J.V.), Leiden University Medical Centre; and Department of Immunology (B.C.J.), Erasmus MC, University Medical Centre Rotterdam, the Netherlands.
Background And Objectives: To investigate CSF findings in relation to clinical and electrodiagnostic subtypes, severity, and outcome of Guillain-Barré syndrome (GBS) based on 1,500 patients in the International GBS Outcome Study.
Methods: Albuminocytologic dissociation (ACD) was defined as an increased protein level (>0.45 g/L) in the absence of elevated white cell count (<50 cells/μL).
Nat Med
April 2023
Division of Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
N Engl J Med
April 2023
From the University of Texas Medical Branch, Galveston (L.D.P., G.R.S., A.S.), the University of Texas Health Science Center at Houston, Children's Memorial Hermann Hospital, Houston (S.P.C.), and the University of Texas at Austin, Austin (G.A.M.) - all in Texas; the George Washington University Biostatistics Center, Washington, DC (R.G.C., S.J.W.); the University of Pennsylvania, Philadelphia (S.P.); the University of North Carolina at Chapel Hill, Chapel Hill (J.M.T.); the Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD (M.L.); MetroHealth Medical Center, Case Western Reserve University, Cleveland (W.D., J.L.B.), and the Ohio State University, Columbus (K.R.) - both in Ohio; the University of Alabama at Birmingham, Birmingham (A.T.N.T.); Columbia University, New York (C.G.-B.); the University of Utah Health Sciences Center, Salt Lake City (T.D.M.); Brown University, Providence, RI (D.J.R.); Northwestern University, Chicago (W.A.G.); and the University of Pittsburgh, Pittsburgh (H.N.S.).
Background: Prophylactic use of tranexamic acid at the time of cesarean delivery has been shown to decrease the calculated blood loss, but the effect on the need for blood transfusions is unclear.
Methods: We randomly assigned patients undergoing cesarean delivery at 31 U.S.
Transl Oncol
June 2023
Department of Surgery, Oregon Health & Science University, 2730 S. Moody Ave, Portland, OR 97201, USA; Brenden-Colson Center for Pancreatic Care, Knight Cancer Institute, Oregon Health & Science University, 2730 S. Moody Ave, Portland, OR 97201, USA. Electronic address:
Introduction: Standard-of-care systemic chemotherapies for pancreatic ductal adenocarcinoma (PDAC) currently have limited clinical benefits, in addition to causing adverse side effects in many patients. One factor known to contribute to the poor chemotherapy response is the poor drug diffusion into PDAC tumors. Novel treatment methods are therefore drastically needed to improve targeted delivery of treatments.
View Article and Find Full Text PDFInt J Mol Sci
March 2023
Department of Pediatrics, School of Oncology and Reproduction (GROW), Maastricht University, 6229 ER Maastricht, The Netherlands.
Perinatal brain injury following hypoxia-ischemia (HI) is characterized by high mortality rates and long-term disabilities. Previously, we demonstrated that depletion of Annexin A1, an essential mediator in BBB integrity, was associated with a temporal loss of blood-brain barrier (BBB) integrity after HI. Since the molecular and cellular mechanisms mediating the impact of HI are not fully scrutinized, we aimed to gain mechanistic insight into the dynamics of essential BBB structures following global HI in relation to ANXA1 expression.
View Article and Find Full Text PDFCirc Genom Precis Med
April 2023
Department of Laboratory Medicine & Pathology, School of Medicine (K.M.B., N.P.), University of Minnesota, Minneapolis.
Background: Risk for venous thromboembolism has a strong genetic component. Whole genome sequencing from the TOPMed program (Trans-Omics for Precision Medicine) allowed us to look for new associations, particularly rare variants missed by standard genome-wide association studies.
Methods: The 3793 cases and 7834 controls (11.
STAR Protoc
December 2022
Broad Institute of MIT and Harvard, Cambridge, MA, USA; Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA, USA; Massachusetts Consortium on Pathogen Readiness, Boston, MA, USA; Department of Immunology and Infectious Disease, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Howard Hughes Medical Institute, Chevy Chase, MD, USA.
Immunopeptidome profiling of infected cells is a powerful technique for detecting viral peptides that are naturally processed and loaded onto class I human leukocyte antigens (HLAs-I). Here, we provide a protocol for preparing samples for immunopeptidome profiling that can inactivate enveloped viruses while still preserving the integrity of the HLA-I complex. We detail steps for lysate preparation of infected cells followed by HLA-I immunoprecipitation and virus inactivation.
View Article and Find Full Text PDF